Abrax has reformulated and optimized MC903 (calcipotriene) and is aiming for approval by the US FDA in the shortest possible time. Although a Japanese bio-venture, Abrax is unique in that it has drawn a roadmap in its global market strategy together with its global partners.
Since its establishment, Abrax Japan has been a bio-venture company that aims to turn discoveries made through research led by Dr. Taku Kambayashi into reality for the promotion of health.
